GEOVAX LABS INC
Geovax Labs Inc (GOVX) is a clinical-stage biotechnology company developing vaccines using a Modified Vaccinia Ankara virus-like particle (MVA‑VLP) platform. The company has focused on infectious disease targets and aims to elicit robust immune responses through its platform. As a micro‑cap (market capitalisation around $17.2m), Geovax is a speculative, early‑stage investment: clinical data, regulatory decisions and financing events tend to be the primary value drivers. Investors should be aware of common biotech risks — trial setbacks, regulatory hurdles, limited revenues and potential dilution from capital raises — alongside the potential upside if clinical proof‑of‑concept is achieved. This summary is for general educational purposes only and not personalised investment advice. Suitability depends on an individual’s risk tolerance, time horizon and portfolio diversification. Past performance is not an indicator of future results; values can fall as well as rise and returns are not guaranteed.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying GEOVAX Labs' stock with a target price of $22.75, indicating significant growth potential.
Financial Health
GeoVax Labs shows modest revenue and cash flow, indicating steady but limited financial performance.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ARCELLX INC
Develops T-cell therapies for the treatment of cancer.
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Baskets Featuring GOVX
Pediatric Vaccine Rollout
This carefully selected group of stocks represents companies positioned to benefit from the full FDA approval of COVID-19 vaccines for at-risk children. Our professional analysts have identified opportunities across the entire value chain, from vaccine manufacturers to healthcare providers and clinical research organizations.
Published: July 11, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Platform Potential
Geovax’s MVA‑VLP platform underpins its vaccine candidates and could offer differentiation if clinical proof emerges, though outcomes are uncertain and long timelines are common.
Clinical Milestones
Trial data and regulatory updates are primary catalysts that can move the stock sharply in either direction; investors should expect binary event risk.
Funding & Liquidity
With a market capitalisation near $17m, Geovax is a micro‑cap with limited liquidity and potential need for further financing, which can dilute existing holders.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
